Subscribe
Be the first with the news that moves the market- The second-leading cause of death among Canadians is heart disease
- Abbott Laboratories (NYSE:ABT) recently acquired Cardiovascular Systems Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease
- The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow
- Abbott Laboratories (ABT) opened trading at $US109.36
The second-leading cause of death among Canadians is heart disease.
According to the Public Health Agency of Canada, 2.6 million adults age 20 and over live with diagnosed heart disease. It can happen when fat and cholesterol plaque builds up in the walls of arteries.
The blood vessels that carry blood between the heart and the rest of the body gets jammed from this buildup that can narrow or block an artery, limit blood flow, and raise the risk for serious health problems.
Smoking, an unhealthy diet, and inactivity are all leading causes.
Early detection and management of medical conditions such as high blood pressure, diabetes, and high cholesterol can help reduce your risk of heart disease and is an opportunity for health firms.
One such business is Abbott Laboratories (NYSE:ABT), who recently acquired Cardiovascular Systems Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow.
“For patients with complex cardiovascular disease, new and innovative therapies such as CSI’s leading atherectomy system are an opportunity to live better, fuller lives,” said Lisa Earnhardt, executive vice president, Medical Devices, Abbott. “The acquisition of CSI is a component of an overall investment in our vascular portfolio that enhances our ability to care for patients with peripheral and coronary artery disease.”
CSI became a wholly owned subsidiary of Abbott.
Abbott Laboratories (ABT) stock has seen 1.6 per cent growth since this time last year and has moved up 5.9 per cent this month. ABT opened trading at $US109.36.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
